Why we are here?

Our vision - to be the clear choice

Our vision is to become an integrated global pharmaceutical company adhering to high standards of quality and compliance

Our mission - the higher purpose

Kimia’s tag line ā€œChemistry of well-beingā€ speaks volumes about the founders’ mission to leverage chemistry for the wellbeing of the people across the globe.

What we believe in?

1491165

Being
empathetic

2618461

Invent and pioneer
for human well being

1851036

Excellence in
everything we do

4185325

Working
together

921439

Improving planet
sustainability

912315

Being honest and
consistent

What we want to be?

The Clear Choice

handshake-xxl

Our customer value
associating with us

document-2-xxl

Our people want to
invest their careers with us

conference-call-xxl

Our communities
trust us

How will we reach there?

1

Constant investment in R&D for innovation

2

Stringent quality
benchmarks

3

Making our processes agile for faster value delivery

4

Nurture and develop our people capabilities

5

Expanding product and service ecosystem with strategic partnerships

6

Embracing sustainable practices to reduce environmental impact

Our Promise

With the purpose of human wellbeing we deliver high quality chemistry solutions,
by blending our customer centric approach with agile production and delivery processes.

Our journey

The secret of a bright future is crafted in the womb of history!

Started R&D and ramped up with 120 people with strong IPR team

2015

Acquisition of Laurel Organics limited, a listed company in 2016.

2016

Accreditation of who GMP in 2019 and DSIR R&D in 2017.

2017

Filed KDMF for 2 key products, Benfotiamine and Fimasartan Potassium Hydrochloride.

2017

Commenced export business in Pakistan 2017 and quickly ramped up exports to more than 15 countries between 2018-2020 and successfully exported to the US in 2021.

2017

Upgraded facility with 2 modern Microbiology labs, Water System, 5 clean room and In house micronization.

2018

Ramped up exports to more than 15 countries

2018-20

Started nutraceutical exports to the U.S.
Developed DCGI-approved APIs; first- and second-time launches in India.
Gained approvals in South Africa, Taiwan.
Business expanded into LATAM & Asia-Pacific.
Launched products in China; filed products in EU.
Filed multipleĀ patents.

2021-2025

Team

Mr. Sameer Goel

Managing Director (MD)

Mr. Sameer Goel is the Managing Director and heading Kimia Biosciences. He holds a tall stature in the Indian API market and has strong multi-dimensional capabilities in the areas of Business Development, Product Development, Strategic Marketing and Operations Management. He has played a key leadership role with various organizations in acquiring and aligning the strong support of professional networks, business partners and executive teams to accomplish expertise in manufacturing, sales, marketing and trading of various APIs and its Intermediates.

Currently, Mr. Goel is responsible for providing overall leadership in achieving business & product development goals and formation of strategic partnerships in Business.

Mr. Vijayasekhar Reddy Kaku

Chief Operating Officer (COO)

Transformational pharmaceutical leader with 40+ years driving operational excellence, greenfield project delivery, and business growth across Active Pharmaceutical Ingredients (API) manufacturing. Proven expertise in building research-driven organizations, scaling operations from concept to commercialization, and navigating complex regulatory landscapes. Strategic architect of multi-million dollar facilities with demonstrated success in process innovation, IP development, and global market expansion.

Dr. Rita Sarin

Advisor – Strategy & IPR Head of Intellectual Property Rights

Dr. Rita Sarin is an Advisor and heading IPR and Strategic Management at Kimia Biosciences Ltd. She is Ph.D. degree in Medicinal Chemistry from Central Drug Research Institute (CDRI), Lucknow and has 24 years of extensive experience in various aspects of Intellectual Property. She has previously worked at Ranbaxy (now Sun Pharma) and Lupin Research Laboratories. She has received an award from the President of India, late Shri Dr. Abdul Kalam Azad in 2012 for the launch of Synriam TM, the first drug developed in India.

KIMIA BIOSCIENCE LIMITED
974, Aggarwal Millennium Tower II,
Netaji Subhash Place, Pitampura,
New Delhi-110 034
+91-11-4706 3600
info@kimiabiosciences.com
sales@kimiabiosciences.com

Kimia Biosciences Ltdā„¢ is a leading manufacturer of bulk drugs focused on high-potential therapeutic segments. The company is pursuing an ambitious growth strategy driven by infrastructure expansion and Contract Development & Manufacturing (CDMO) initiatives.